ELISA Kit for Bone Morphogenetic Protein 7 (BMP7)
OP1; Osteogenic Protein-1; Eptotermin alfa
- UOM
- FOB US$ 479.00 US$ 684.00 US$ 3,078.00 US$ 5,814.00 US$ 47,880.00
- Quantity
Overview
Properties
- Product No.SEA799Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- ApplicationsEnzyme-linked immunosorbent assay for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryMetabolic pathwayDevelopmental scienceBone metabolism
Sign into your account
Share a new citation as an author
Upload your experimental result
Review

Contact us
Please fill in the blank.
Recovery
Matrices listed below were spiked with certain level of recombinant Bone Morphogenetic Protein 7 (BMP7) and the recovery rates were calculated by comparing the measured value to the expected amount of Bone Morphogenetic Protein 7 (BMP7) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 94-102 | 97 |
EDTA plasma(n=5) | 98-105 | 101 |
heparin plasma(n=5) | 85-103 | 89 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Bone Morphogenetic Protein 7 (BMP7) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Bone Morphogenetic Protein 7 (BMP7) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Bone Morphogenetic Protein 7 (BMP7) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 98-105% | 94-105% | 96-103% | 85-97% |
EDTA plasma(n=5) | 78-96% | 90-98% | 95-103% | 80-101% |
heparin plasma(n=5) | 86-104% | 95-104% | 87-98% | 97-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.

Test principle
The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Bone Morphogenetic Protein 7 (BMP7). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Bone Morphogenetic Protein 7 (BMP7). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Bone Morphogenetic Protein 7 (BMP7), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Bone Morphogenetic Protein 7 (BMP7) in the samples is then determined by comparing the O.D. of the samples to the standard curve.
Giveaways
Increment services
-
Single-component Reagents of Assay Kit
-
Lysis Buffer Specific for ELISA / CLIA
-
Quality Control of Kit
-
ELISA Kit Customized Service
-
Disease Model Customized Service
-
Serums Customized Service
-
TGFB1 Activation Reagent
-
Real Time PCR Experimental Service
-
Streptavidin
-
Fast blue Protein Stain solution
-
Single-component Reagents of FLIA Kit
-
Streptavidin-Agarose Beads
Citations
- A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic ApproachesPlosone: Source
- Serum Heme Oxygenase-1 and BMP-7 Are Potential Biomarkers for Bone Metabolism in Patients with Rheumatoid Arthritis and Ankylosing SpondylitisPubmed:27314037
- The dose-time effects of fluoride on the expression and DNA methylation level of the promoter region of BMP-2 and BMP-7 in ratsPubmed: 32004919
- Temporal TGF-β Supergene Family Signalling Cues Modulating Tissue Morphogenesis: Chondrogenesis within a Muscle Tissue Model?Pubmed: 32660137